Sublocade Solution
Product Images NDC 12496-0300

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Sublocade (NDC 12496-0300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Indivior Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sub0a 0038 01

An instructional illustration showing a syringe attached to a safety needle device, likely depicting preparation or administration details for a subcutaneous solution drug. The image emphasizes the syringe and safety needle components.*

FDA Label Image

Sub0a 0038 02

An instructional diagram depicting a syringe with a solution, with an eye icon indicating visual inspection of the syringe content. The syringe is drawn with a focus on the barrel and plunger, suggesting the step of checking the medication before administration.*

FDA Label Image

Sub0a 0038 03

An instructional illustration showing a syringe with solution being drawn and inserted into a vial, indicated by a downward arrow. This image relates to preparation or administration steps for SUBLOCADE (buprenorphine) subcutaneous solution.*

FDA Label Image

Sub0a 0038 04

An anatomical illustration showing the lower abdominal region marked with the 'Transpyloric Plane' and 'Transtubercular Plane'. The diagram labels four numbered quadrants or injection sites around the abdomen, likely indicating areas for subcutaneous administration.*

FDA Label Image

Sub0a 0038 05

An illustration showing a syringe being used to withdraw or inject solution into a vial. The drawing depicts the syringe insert into the vial's rubber stopper, typically for preparation or administration of a medication, such as a subcutaneous injection.*

FDA Label Image

Sub0a 0038 06

An instructional line drawing showing the proper technique for administering a subcutaneous injection into the abdominal area. A hand is pulling the skin to create a fold above the injection site on the lower abdomen, indicating preparation for injection.*

FDA Label Image

Sub0a 0038 07

An instructional illustration showing an injection technique for a subcutaneous solution. The image depicts a hand holding a syringe, directed at a forearm, with a note indicating a 45-degree angle.*

FDA Label Image

Sub0a 0038 08

An instructional illustration showing the administration of a subcutaneous injection. The image depicts a hand holding a syringe injecting a solution into the abdominal area of a patient. This depicts proper technique for subcutaneous injection of a drug such as SUBLOCADE (buprenorphine) solution.*

FDA Label Image

Sub0a 0038 09

An instructional line drawing showing a hand holding a syringe angled toward the skin, illustrating the subcutaneous injection technique likely related to administering SUBLOCADE (buprenorphine) solution.*

FDA Label Image

Sub0a 0038 10

Chemical structure of the active ingredient buprenorphine, shown as a complex multi-ring molecular diagram with various functional groups including hydroxyl, methoxy, and nitrogen-containing groups.*

FDA Label Image

Sub0a 0038 11

Scatter plot showing Placebo-Corrected VAS Drug-Liking Scores versus Buprenorphine Plasma Concentration after SUBLOCADE injection. Data points compare baseline measurements with no buprenorphine and weeks 1-12 post-injection. Scores (mm) are plotted on the y-axis and plasma concentration (ng/mL) on the x-axis.*

FDA Label Image

Sub0a 0038 12

A bar chart showing the percentage response rates for four doses of fentanyl across five experimental groups: placebo (PBO), low buprenorphine (Low BUP, 1 ng/mL), mid buprenorphine (Mid BUP, 2 ng/mL), and high buprenorphine (High BUP, 5 ng/mL). The chart compares the effect of buprenorphine concentration on fentanyl dosing.*

FDA Label Image

Sub0a 0038 13

A two-part line and scatter plot chart showing placebo-corrected VAS drug liking scores over a 12-week period for SUBLOCADE 300 mg compared to 6 mg and 18 mg hydromorphone doses. The horizontal axis represents time in weeks, starting from baseline through Week 12, while the vertical axis measures the drug liking score in millimeters. The upper chart shows median differences with 95% confidence intervals, and the lower chart presents individual data points for the two hydromorphone doses.*

FDA Label Image

Sub0a 0038 14

A Kaplan-Meier curve graph displaying the percentage of subjects with opioid-free weeks over time. The graph compares three groups: SUBLOCADE 300 mg/300 mg + IDC, SUBLOCADE 300 mg/100 mg + IDC, and Placebo + IDC. The x-axis represents the percentage of opioid-free weeks, and the y-axis shows the percentage of subjects, highlighting differences in opioid abstinence among the groups.*

FDA Label Image

Sub0a 0038 15

SUBLOCADE 100 mg solution for subcutaneous injection carton, containing buprenorphine extended-release. The label highlights its use for abdominal subcutaneous injection only, with warnings about serious harm or death if injected intravenously. Manufacturer information identifies Indivior Inc. Storage instructions and dosing caution are included on the package sides.*

FDA Label Image

Sub0a 0038 16

Label for SUBLOCADE 100 mg solution for subcutaneous injection by Indivior Inc. This sterile, single-dose prefilled syringe contains buprenorphine extended-release in the ATRIGEL delivery system. The label includes storage instructions and manufacturer details, emphasizing abdominal subcutaneous injection only.*

FDA Label Image

Sub0a 0038 17

Label for SUBLOCADE 100 mg solution for subcutaneous injection, buprenorphine extended-release by Indivior Inc. The label indicates single dose, sterile product with lot number and expiration date fields, and includes manufacturer information: AMRI, Burlington, MA. The label also features a linear barcode area and a note for position on packaging wrap.*

FDA Label Image

Sub0a 0038 18

Packaging label for SUBLOCADE 300 mg solution for subcutaneous injection. The label states the product contains buprenorphine extended-release and is for human prescription use. It includes dosage instructions, storage information, a warning about serious harm or death if injected intravenously, and labeler information for Indivior Inc. The package is designed for a single dose with NDC 12496-0300-1.*

FDA Label Image

Sub0a 0038 19

Label for SUBLOCADE 300 mg solution for subcutaneous injection, a buprenorphine extended-release product by Indivior Inc. The label states it is a single-dose sterile syringe prefilled with 300 mg/1.5 mL (200 mg/mL) and intended for abdominal subcutaneous use only. Storage instructions include refrigeration at 2°-8°C and room temperature storage up to 7 days before administration.*

FDA Label Image

Sub0a 0038 20

Label for SUBLOCADE 300 mg solution for subcutaneous injection by Indivior Inc., single dose and sterile. Includes usage instructions, manufacturer information (AMRI, Burlington, MA), lot number placeholder, expiration date 12/2017, and a linear barcode area.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.